Vivos (RDGL) Profit After Tax Growth (3y) (2013 - 2025)
Vivos (RDGL) Profit After Tax Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -2.39% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 62.16% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 3.79% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 30.85% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 60.12% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 3.38% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 6.53% |
| 10 | Vivos | - | - | -3,105.00 | -15.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.19% |
| Sep 30, 2025 | -22.34% |
| Jun 30, 2025 | 6.41% |
| Mar 31, 2025 | -6.05% |
| Dec 31, 2024 | -79.06% |
| Sep 30, 2024 | -60.08% |
| Jun 30, 2024 | 35.32% |
| Mar 31, 2024 | -24.68% |
| Dec 31, 2023 | -52.73% |
| Sep 30, 2023 | -70.13% |
| Jun 30, 2023 | -78.35% |
| Mar 31, 2023 | 11.66% |
| Dec 31, 2022 | -11.87% |
| Sep 30, 2022 | 25.47% |
| Jun 30, 2022 | -57.83% |
| Mar 31, 2022 | -43.60% |
| Dec 31, 2021 | -26.14% |
| Sep 30, 2021 | 80.45% |
| Jun 30, 2021 | 32.36% |
| Mar 31, 2021 | 31.62% |